PASylated biopharmaceutical (licensed to Grifols)
Undisclosed
Pre-clinicalActive
Key Facts
About XL-protein
XL-protein is a privately held German biotech specializing in half-life extension technology. Its proprietary PASylation platform offers a biodegradable, polypeptide-based alternative to traditional PEGylation for improving therapeutic proteins. The company operates primarily as a platform and partnering business, out-licensing its technology for preclinical and clinical development across multiple disease areas, as evidenced by its recent license agreement with Grifols.
View full company profileOther Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |